Description
Risankizumab has been shown to be safe and effective for the treatment of psoriasis in numerous randomized clinical trials and real-life studies. Real-life data on treatment for up to 4 years are lacking.The present study aims to estimate the drug survival (DS), effectiveness, and safety of risankizumab over a period of 208 weeks (W).We included all consecutive patients with psoriasis or psoriatic arthritis receiving at least 1 dose of risankizumab. Effectiveness was evaluated according to the achievement of PASI 100 and PASI 90. DS was evaluated by a Kaplan-Meyer curve.A total of 545 patients were included in the study. Mean PASI decreased from 14 at baseline to 0.5 at 208W. PASI100 showed an increasing response, which was achieved in 33% and 74% of patients at 16W and 208W, respectively. For PASI90 a similar trend was seen, with a peak at 208W of 81% patients achieving the outcome. The estimated DS at 208W was 87.2% in patients at risk. Bio-naïve patients showed a significantly faster response than bio-experienced patients. Obesity and difficult-to-treat involvement seem to slow the response, with patients with difficult-site involvement having a lower risk of drug interruption (HR 0.15, CI 0.07-0.31, pOur study confirms the good effectiveness and favorable safety of risankizumab in a real-world setting for up to four years.
Source URL: